Updated:
Ionis Pharmaceuticals
Ionis Pharmaceuticals pioneers RNA- and DNA-targeted medicines. Pipeline includes neurologic, cardiometabolic, and rare disease programs.
Ionis Pharmaceuticals
Founded in 1989, Ionis Pharmaceuticals is led by CEO Brett P. Monia, who succeeded Stanley T. Crooke, the company's original founder and long-time chief. The wealth origin is corporate; Ionis is a publicly traded biotechnology firm (Nasdaq: IONS) with no disclosed family-office backing. Ionis pursues RNA- and DNA-targeted medicines using its proprietary antisense technology platform. Its pipeline covers over 40 programs in neurology, cardiometabolic disease, and rare genetic disorders. The company has brought several drugs to market, including Spinraza for spinal muscular atrophy (developed with Biogen) and Tegsedi for hereditary transthyretin amyloidosis. Ionis also partners with AstraZeneca, Novartis, and Johnson & Johnson (per company filings, 2025). Geographically, its footprint includes the United States and Europe. The company employs approximately 1,500 people across five offices: Carlsbad (HQ), New Brunswick, Cleveland, Stockholm, New York, and Cambridge. Ionis does not operate as a multi-family office or philanthropic vehicle; its activities are strictly pharmaceutical R&D and commercialization. A May 2026 corporate update highlighted progress in cardiovascular pipeline data (per the firm, May 2026). Ionis's structural differentiator is its antisense chemistry platform, which allows it to design drugs that modulate RNA at the genetic level. This gives the company a unique position in the biotech ecosystem, as it can target traditionally undruggable diseases, though it carries the risks of clinical-stage biotech.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Additional offices
New Brunswick · Cleveland · Stockholm · New York · Cambridge
Sector focus
Frequently asked questions
Is Ionis Pharmaceuticals a family office or an asset manager?
Ionis Pharmaceuticals is a publicly traded biotechnology company (Nasdaq: IONS), not a family office or asset manager. Its focus is on developing RNA- and DNA-targeted medicines for serious diseases.
What investment stages does Ionis Pharmaceuticals target?
Ionis does not make investments in external companies. It develops its own drug candidates from discovery through clinical trials and seeks partnerships with larger pharmaceutical firms for late-stage development and commercialization.
Who leads investment decisions at Ionis Pharmaceuticals?
CEO Brett P. Monia leads the company's strategic direction. Research and development decisions are made by internal scientific leadership, including Chief Scientific Officer Frank Bennett (per company filings, 2025).
How does Ionis Pharmaceuticals source its drug pipeline?
Ionis internally discovers and develops drug candidates using its proprietary antisense technology platform. The company also engages in partnerships and licensing agreements with other biopharma firms to expand its pipeline.
What therapeutic areas does Ionis Pharmaceuticals focus on?
Ionis concentrates on neurology, cardiometabolic disorders, and rare genetic diseases. The company also explores select high-need conditions where its RNA-targeting approach may offer a first-in-class treatment.
Does Ionis Pharmaceuticals explicitly avoid any sectors?
Ionis focuses strictly on RNA- and DNA-targeted therapeutics. It does not operate in oncology, vaccines, or small molecule drugs outside its core platform (per the firm's pipeline disclosures, 2025).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: